Repligen Corporation (RGEN) Is At All Time High at $47.67

June 29, 2018 - By Glen Chin

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

During 2018 Q1 the big money sentiment increased to 1.39. That’s change of 0.13, from 2017Q4’s 1.26. 13 investors sold all, 46 reduced holdings as Repligen Corporation ratio is positive. 63 increased holdings while 19 funds took holdings. Funds hold 35.98 million shares thus 2.25% more from 2017Q4’s 35.19 million shares.
Blackrock reported 5.37 million shs. Prudential holds 63,565 shs or 0% of its capital. Utd Automobile Association reported 0.01% in Repligen Corporation (NASDAQ:RGEN). Eaton Vance Management has invested 0% of its capital in Repligen Corporation (NASDAQ:RGEN). Victory Capital Management Inc has 0% invested in Repligen Corporation (NASDAQ:RGEN). First Mercantile Tru reported 0.02% of its capital in Repligen Corporation (NASDAQ:RGEN). Arizona State Retirement Systems has 59,171 shs. Fred Alger Management has 377,235 shs for 0.06% of their capital. 1,101 were accumulated by Employees Retirement Association Of Colorado. Virginia Retirement Et Al reported 28,000 shs. Mutual Of America Capital Mgmt Lc, New York-based fund reported 84,456 shs. Ranger Investment Management Ltd Partnership accumulated 691,422 shs. Moreover, Credit Suisse Ag has 0% invested in Repligen Corporation (NASDAQ:RGEN) for 40,643 shs. Putnam Limited Liability Com reported 38,673 shs. State Of Wisconsin Invest Board reported 37,700 shs stake.

Repligen Corporation registered $13.05 million net activity with 0 insider purchases and 8 selling transactions since January 22, 2018. On Friday, May 11 20,000 shs were sold by DAWES KAREN A, worth $835,936. On Wednesday, June 6 RYAN THOMAS F JR sold $85,606 worth of Repligen Corporation (NASDAQ:RGEN) or 1,932 shs. The insider Hunt Anthony sold $691,016. BARTHELEMY NICOLAS also sold $1.07 million worth of Repligen Corporation (NASDAQ:RGEN) on Wednesday, May 9.

By reaching $47.67 share price all time high was [achieved] by Repligen Corporation (NASDAQ:RGEN). announced it. The company has $2.08 billion MC. $124.98M more could be NASDAQ:RGEN valuation at $50.53 share price.

RGEN is reaching $47.67 during the last trading session, after increased 1.87%.Repligen Corporation has volume of 155,508 shares. Since June 29, 2017 RGEN has risen 11.84% and is uptrending. RGEN underperformed by 0.73% the S&P 500.

Investors wait Repligen Corporation (NASDAQ:RGEN)’s quarterly earnings on August, 2., Zacks reports. Analysts predict $0.19 earnings per share, which is $0.01 down or 5.00 % from 2017’s $0.2 earnings per share. If earnings per share of $0.19 is revealed the profit of RGEN could reach $8.30M giving it 62.72 P/E. Wall Street now predicts 11.76 % EPS growth despite Repligen Corporation previous quarter’s EPS of $0.17.

A couple more Repligen Corporation (NASDAQ:RGEN) news were announced by: which released on June 11, 2018 “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …”, also on June 27, 2018 announced “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, the next is “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand” on June 28, 2018. has article titled “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The firm is worth $2.08 billion. It makes various forms of Protein A, a critical component used to purify antibody drugs.The P/E ratio is 66.22. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.